Alumis
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Alumis and other ETFs, options, and stocks.About ALMS
Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies.
CEOMartin Babler
CEOMartin Babler
Employees168
Employees168
HeadquartersSan Francisco, California
HeadquartersSan Francisco, California
Founded2021
Founded2021
Employees168
Employees168
ALMS Key Statistics
Market cap1.89B
Market cap1.89B
Price-Earnings ratio-4.65
Price-Earnings ratio-4.65
Dividend yield—
Dividend yield—
Average volume8.16M
Average volume8.16M
High today$19.00
High today$19.00
Low today$17.44
Low today$17.44
Open price$18.25
Open price$18.25
Volume9.89M
Volume9.89M
52 Week high$22.30
52 Week high$22.30
52 Week low$2.76
52 Week low$2.76
Stock Snapshot
Alumis(ALMS) stock is priced at $18.12, giving the company a market capitalization of 1.89B. It carries a P/E multiple of -4.65.
As of 2026-01-08, Alumis(ALMS) stock has fluctuated between $17.44 and $19.00. The current price stands at $18.12, placing the stock +3.9% above today's low and -4.6% off the high.
The Alumis(ALMS)'s current trading volume is 9.89M, compared to an average daily volume of 8.16M.
During the past year, Alumis(ALMS) stock moved between $2.76 at its lowest and $22.30 at its peak.
During the past year, Alumis(ALMS) stock moved between $2.76 at its lowest and $22.30 at its peak.
Analyst ratings
100%
of 8 ratingsBuy
100%
Hold
0%
Sell
0%
People also own
Based on the portfolios of people who own ALMS. This list is generated using Robinhood data, and it’s not a recommendation.